Search
SYNB1353
go.drugbank.com/drugs/DB17666InvestigationalSYNB1353 is a strain of the probiotic bacteria _Escherichia coli_ (_E. coli_) type Nissle and an engineered probiotic drug. … It is designed to consume methionine in the gastrointestinal tract to prevent its absorption and conversion into homocysteine.[L45983]
Anti-SARS-CoV-2 IgY
go.drugbank.com/drugs/DB16356Investigational[L27381] To create these antibodies, chickens are injected in the chest with the spike protein, which is the surface protein of SARS-CoV-2; this results in an immune response mounted by the chickens towards … These antibodies are currently being investigated against COVID-19 in the trial NCT04567810 (Safety, Tolerability, and Pharmacokinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV
Amolimogene bepiplasmid
go.drugbank.com/drugs/DB04904InvestigationalAmolimogene is an investigational therapeutic designed to specifically augment the body's defensive response to human papillomavirus (HPV).
Tersolisib
go.drugbank.com/drugs/DB21752InvestigationalSTX-478 is under investigation in clinical trail NCT05768139 (First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Necuparanib
go.drugbank.com/drugs/DB16251InvestigationalNecuparanib is under investigation in clinical trial NCT01621243 (M402 in Combination With Nab-paclitaxel and Gemcitabine in Pancreatic Cancer).
ABX-196
go.drugbank.com/drugs/DB16339InvestigationalABX-196 is under investigation in clinical trial NCT03897543 (ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma).
Stepronin
go.drugbank.com/drugs/DB01423ExperimentalThe viscosity of mucous secretions in the lungs is dependent upon the concentrations of mucoprotein as well as the presence of disulfide bonds between these macromolecules and DNA.
Mesmulogene ancovacivec
go.drugbank.com/drugs/DB06584Investigationalwith MVA-MUC1-IL2 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) responses against tumor cells expressing MUC1, a tumor associated antigen, resulting in
Nedisertib
go.drugbank.com/drugs/DB16252InvestigationalNedisertib is under investigation in clinical trial NCT03770689 (Study of M3814 in Combination With Capecitabine and Radiotherapy in Rectal Cancer).